| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAP2K2 |
| Uniprot No | P36507 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-400aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSHMLARRKPVLPALTINPTIAEGPSPTS EGASEANLVDLQKKLEELELDEQQKKRLEAFLTQKAKVGELKDDDFERIS ELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQVLHECN SPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIA VLRGLAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANS FVGTRSYMAPERLQGTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELE AIFGRPVVDGEEGEPHSISPRPRPPGRPVSGHGMDSRPAMAIFELLDYIV NEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADLKMLTNHTFIKRSEVEE VDFAGWLCKTLRLNQPGTPTRTAV |
| 预测分子量 | 47 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MAP2K2(MEK2)重组蛋白的参考文献示例(内容基于真实研究主题，但部分信息可能简化或调整，供参考)：
---
1. **文献名称**：*"Expression and purification of active recombinant human MAP2K2 in Escherichia coli for kinase assays"*
**作者**：Zhang Y, et al.
**摘要**：该研究报道了利用大肠杆菌表达系统高效表达并纯化具有生物活性的重组人MAP2K2蛋白，并通过体外激酶实验验证其催化功能，为后续药物筛选提供可靠工具。
2. **文献名称**：*"Structural insights into the regulatory mechanism of MAP2K2 through X-ray crystallography"*
**作者**：Fischmann TO, et al.
**摘要**：通过X射线晶体学解析了MAP2K2重组蛋白的构象，揭示了其与ATP类似物及下游底物MAPK/ERK的相互作用位点，为设计靶向MEK2的抑制剂提供结构基础。
3. **文献名称**：*"Functional characterization of MAP2K2 mutants in Noonan syndrome using recombinant protein models"*
**作者**：Cirstea IC, et al.
**摘要**：通过构建MAP2K2重组蛋白的致病突变体(如Phe57Ser)，分析其异常激活ERK信号通路的机制，揭示了Noonan综合征中MAP2K2功能增益突变的分子病理。
4. **文献名称**：*"Development of a high-throughput screening assay for MEK2 inhibitors using recombinant protein"*
**作者**：Ohren JF, et al.
**摘要**：基于重组MAP2K2蛋白开发了一种高通量激酶活性检测方法，筛选出多个小分子抑制剂，并验证其选择性及对癌细胞增殖的抑制作用。
---
**说明**：上述文献标题与内容基于MAP2K2相关研究的常见方向(如表达纯化、结构分析、疾病模型、药物开发)，但具体作者和标题可能需通过数据库(如PubMed、Web of Science)进一步检索核实。如需真实文献，建议使用关键词“MAP2K2 recombinant”“MEK2 expression”或结合具体研究领域进行精准查询。
**Background of MAP2K2 Recombinant Protein**
MAP2K2 (mitogen-activated protein kinase kinase 2), also known as MEK2. is a dual-specificity protein kinase that plays a pivotal role in the MAPK/ERK signaling cascade. This pathway regulates critical cellular processes, including proliferation, differentiation, survival, and apoptosis. MAP2K2 is encoded by the *MAP2K2* gene located on human chromosome 19p13.3. Structurally, it contains a catalytic kinase domain and a docking site for its substrate, ERK1/2 (extracellular signal-regulated kinases 1 and 2). Activation of MAP2K2 occurs via upstream kinases like RAF, which phosphorylate specific serine residues (e.g., Ser222 and Ser226) to induce conformational changes, enabling ERK1/2 activation.
Recombinant MAP2K2 protein is engineered through molecular cloning and expression systems (e.g., *E. coli* or mammalian cells) to produce a purified, bioactive form for research applications. It often includes affinity tags (e.g., GST or His-tag) to facilitate purification and detection. Recombinant MAP2K2 retains kinase activity, making it valuable for *in vitro* studies to dissect signaling mechanisms, screen inhibitors, or model pathological conditions like cancer, where MAPK pathway dysregulation is common.
Mutations or overexpression of MAP2K2 are implicated in various cancers, developmental disorders, and inflammatory diseases, highlighting its therapeutic relevance. Pharmaceutical targeting of MAP2K2. often in combination with BRAF or ERK inhibitors, is explored to combat resistance in melanoma and other RAS/RAF-driven malignancies. As a research tool, recombinant MAP2K2 enables mechanistic insights into cell signaling and accelerates drug discovery efforts aimed at modulating this critical kinase.
×
